Joshua S. Schiffman

Joshua S. Schiffman

Auto-generated profile, based on publicly available information

Joshua S. Schiffman

New York Genome Center, New York, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RCRonan Chaligne
Ronan Chaligne
FGFederico Gaiti
Federico Gaiti
DSDana Silverbush
Dana Silverbush
JSJoshua S. Schiffman
Joshua S. Schiffman
HWHannah R. Weisman
Hannah R. Weisman
DLDan A. Landau
Dan A. Landau

14 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AWAdam J. Widman
Adam J. Widman
MSMinita Shah
Minita Shah
AFAmanda Frydendahl
Amanda Frydendahl
DHDaniel Halmos
Daniel Halmos
CKCole C. Khamnei
Cole C. Khamnei
DLDan A. Landau
Dan A. Landau
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of ctDNA fragments in low tumor fraction (TF) settings and increase MRD sensitivity, we previously leveraged genome-wide mutational integration through plasma whole-genome sequencing (WGS). Here we now introduce MRD-EDGE, a machine-learning-guided WGS ctDNA single-nucleotide variant (SNV) and copy-number variant (CNV) detection platform designed to increase signal enrichment. MRD-EDGESNV uses deep learning and a ctDNA-specific feature space to increase SNV signal-to-noise enrichment in WGS by ~300× compared to previous WGS error suppression. MRD-EDGECNV also reduces the degree of aneuploidy needed for ultrasensitive CNV detection through WGS from 1 Gb to 200 Mb, vastly expanding its applicability within solid tumors. We harness the improved performance to identify MRD following surgery in multiple cancer types, track changes in TF in response to neoadjuvant immunotherapy in lung cancer and demonstrate ctDNA shedding in precancerous colorectal adenomas. Finally, the radical signal-to-noise enrichment in MRD-EDGESNV enables plasma-only (non-tumor-informed) disease monitoring in advanced melanoma and lung cancer, yielding clinically informative TF monitoring for patients on immune-checkpoint inhibition.

16 September 2021 in Evolution
Verified
Journal Article
Open access
PDF file
JSJoshua S. Schiffman
Joshua S. Schiffman
PRPeter L. Ralph
Peter L. Ralph
Even if a species' phenotype does not change over evolutionary time, the underlying mechanism may change, as distinct molecular pathways can realize identical phenotypes. Here we use linear system theory to explore the consequences of this idea, describing how a gene network underlying a conserved phenotype evolves, as the genetic drift of small changes to these molecular pathways causes a population to explore the set of mechanisms with identical phenotypes. To do this, we model an organism's internal state as a linear system of differential equations for which the environment provides input and the phenotype is the output, in which context there exists an exact characterization of the set of all mechanisms that give the same input–output relationship. This characterization implies that selectively neutral directions in genotype space should be common and that the evolutionary exploration of these distinct but equivalent mechanisms can lead to the reproductive incompatibility of independently evolving populations. This evolutionary exploration, or system drift, is expected to proceed at a rate proportional to the amount of intrapopulation genetic variation divided by the effective population size (Ne). At biologically reasonable parameter values this could lead to substantial interpopulation incompatibility, and thus speciation, on a time scale of Ne generations. This model also naturally predicts Haldane's rule, thus providing a concrete explanation of why heterogametic hybrids tend to be disrupted more often than homogametes during the early stages of speciation. This article is protected by copyright. All rights reserved

24 September 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JSJoshua S. Schiffman
Joshua S. Schiffman
ADAndrew R. D’avino
Andrew R. D’avino
TPTamara Prieto
Tamara Prieto
YPYakun Pang
Yakun Pang
YFYilin Fan
Yilin Fan
DLDan A. Landau
Dan A. Landau

30 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJoshua S. Schiffman
Joshua S. Schiffman
ADAndrew R. D’avino
Andrew R. D’avino
TPTamara Prieto
Tamara Prieto
YPYakun Pang
Yakun Pang
YFYilin Fan
Yilin Fan
DLDan A. Landau
Dan A. Landau
Summary: The broad application of single-cell RNA sequencing has revealed transcriptional cell state heterogeneity across diverse healthy and malignant somatic tissues. Recent advances in lineage tracing technologies have further enabled the simultaneous capture of cell transcriptional state along with cellular ancestry thus enabling the study of somatic evolution at an unprecedented resolution; however, new analytical approaches are needed to fully harness these data. Here we introduce PATH (Phylogenetic Analysis of Transcriptional Heritability), an analytical framework, which draws upon classic approaches in species evolution, to quantify heritability and plasticity of somatic phenotypes, including transcriptional states. The PATH framework further allows for the inference of cell state transition dynamics by linking a model of cellular evolutionary dynamics with our measure of heritability versus plasticity. We evaluate the robustness of this approach by testing a range of biological and technical features in simulations of somatic evolution. We then apply PATH to characterize previously published and newly generated single-cell phylogenies, reconstructed from either native or artificial lineage markers, with matching cellular state profiling. PATH recovered developmental relationships in mouse embryogenesis, and revealed how anatomic proximity influences neural relatedness in the developing zebrafish brain. In cancer, PATH dissected the heritability of the epithelial-to-mesenchymal transition in a mouse model of pancreatic cancer, and the heritability versus plasticity of transcriptionally-defined cell states in human glioblastoma. Finally, PATH revealed phenotypic heritability patterns in a phylogeny reconstructed from single-cell whole genome sequencing of a B-cell acute lymphoblastic leukemia patient sample. Altogether, by bringing together perspectives from evolutionary biology and emerging single-cell technologies, PATH formally connects the analysis of cell state diversity and somatic evolution, providing quantification of critical aspects of these processes and replacing qualitative conceptions of “plasticity” with quantitative measures of cell state transitions and heritability.

22 June 2026 in Nature Genetics
Verified
Journal Article
Open access
MNMasashi Nomura
Masashi Nomura
RRRamya Raviram
Ramya Raviram
JSJoshua S. Schiffman
Joshua S. Schiffman
LBLillian Bussema
Lillian Bussema
VLVivian Lu
Vivian Lu
MSMario L. Suvà
Mario L. Suvà
The progression of isocitrate dehydrogenase-mutant glioma (IDH-G) from slow-growing tumor to fatal disease is associated with transcriptional and DNA methylation changes that remain poorly understood. Here, we profiled a longitudinal cohort of 36 IDH-G samples from 19 patients by joint-capture multi-omic single-nucleus DNA methylation, single-nucleus RNA sequencing and bulk exome sequencing. We show that IDH-G progression is associated with an increase in malignant stem-like states, decreased differentiation and methylation loss, which marks tumors with worse clinical outcome. Methylation loss was uniformly observed across malignant cells within individual tumors, suggesting that it may underlie rather than result from the increase in stem-like states. Analysis of cell-state heritability and plasticity using high-resolution phylogenetic trees links DNA methylation loss to alterations in glioma cell-state encoding and heritability. Our study offers insights into how DNA methylation loss reshapes cellular transitions and how it may mark clinically more aggressive tumors across IDH-G subsets.